With the support of the National Research, Development and Innovation Fund (NKFI Fund), Pharmacenter Hungary Kft. has developed two particularly important oncological drugs, whose development began on October 1, 2021, and was successfully completed on September 30, 2025, the company reported.
The importance of these drugs for healthcare is demonstrated by the fact that one of them was added to the EU’s list of critical medicines in December 2023.
The availability of the drug from various sources for Hungarian patients makes it extremely important for security of supply.
Among other things, this drug is used to treat chronic myeloid leukemia and squamous cell carcinoma in the head and neck area. The development and start of series production of the product as part of the project have been successfully completed, and it is already commercially available, according to the announcement.
Another pillar of development is the drug containing the active ingredient bisphosphonate, which can be used to prevent bone damage caused by metastatic tumors and to reduce the high calcium levels caused by tumors.
Photo: Pixabay
Pharmacenter has uniquely developed a ready-to-use drug that increases patient safety and reduces the burden on the healthcare system. The marketing authorization application for the drug has been submitted in Hungary, and long-term stability studies are currently underway.
Pharmacenter Hungary Kft.’s goal is to ensure a continuous supply of affordable and modern medicines to Hungarian patients, particularly in the field of oncological therapies.
Another strategic goal of the company is to exploit the results of its developments on export markets, thereby strengthening the international presence of the Hungarian pharmaceutical industry.
The now completed project not only means the market launch of two new cancer drugs that fill a gap in the market, but also gives Hungarian patients access to the most modern and safest drug therapies, the company emphasized. According to the information on the website, there are only a few competitors that can match the results of the project, and these are also significantly more expensive – up to 400 percent.
Related article
Pharma Giant Richter’s Shares Surge after U.S. Drug Approval
The approvals mark an important milestone accomplishment for the pharma giant as its first FDA-approved biosimilars.Continue reading
Via MTI; Featured image: Pixabay
